243 related articles for article (PubMed ID: 30521987)
1. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.
Yang C; Arnold AG; Trottier M; Sonoda Y; Abu-Rustum NR; Zivanovic O; Robson ME; Stadler ZK; Walsh MF; Hyman DM; Offit K; Zhang L
Breast Cancer Res Treat; 2016 Dec; 160(3):447-456. PubMed ID: 27757719
[TBL] [Abstract][Full Text] [Related]
4. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
[TBL] [Abstract][Full Text] [Related]
5. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
[TBL] [Abstract][Full Text] [Related]
6. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
8. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
[TBL] [Abstract][Full Text] [Related]
9. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
[TBL] [Abstract][Full Text] [Related]
10. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
11. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
12. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
[TBL] [Abstract][Full Text] [Related]
13. [PALB2 as Another Candidate Gene for Genetic Testing in Patients with Hereditary Breast Cancer in Czech Republic].
Janatová M; Borecká M; Soukupová J; Kleiblová P; Stříbrná J; Vočka M; Zemánková P; Panczak A; Veselá K; Souček P; Foretová L; Kleibl Z
Klin Onkol; 2016; 29 Suppl 1():S31-4. PubMed ID: 26691940
[TBL] [Abstract][Full Text] [Related]
14. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
15. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
16. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
19. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
20. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
